<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053687</url>
  </required_header>
  <id_info>
    <org_study_id>rmc082116ctil</org_study_id>
    <nct_id>NCT03053687</nct_id>
  </id_info>
  <brief_title>Effect of Nutritional Formula Supplementation on Growth Rate of Growth Hormone (GH) Treated Children With Growth Hormone Deficiency (GHD) After the Second Year of Therapy</brief_title>
  <official_title>Effect of Nutritional Formula Supplementation on Growth Rate of Growth Hormone (GH) Treated Children With Growth Hormone Deficiency (GHD) After the Second Year of Therapy- a Randomized Double Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Proposed study is a double blind, randomized, placebo controlled study The aim of the
      study is to evaluate the effect of combined Growth Hormone (GH) treatment &amp; nutritional
      formula supplementation versus GH &amp; placebo on growth parameters in 64 children with Isolated
      Growth Hormone Deficiency (IGHD) after the 2nd year of GH treatment.

      In this trial GH is a background treatment (non-investigational medicinal product.
      Participants may be treated with any of the commercial GH products approved in Israel for the
      indication of IGHD.

      Participants will be randomly assigned either to the intervention group or the placebo
      control group. Randomization for the two study groups will be made in a ratio of 1:1. Both
      participants and study team will be blinded to the type of treatment that each patient will
      receive during the study. The randomization will be done according to gender and tanner
      stage.

      Participants in the intervention groups will be treated with the study formulas and
      participants in the control group will be treated with a placebo low caloric formulas (Powder
      added to water) The study will continue for 6 months of intervention versus active placebo,
      with additional 6 months (an extension period), in which participants at both groups, the
      intervention and the placebo, will be offered to continue their participation in the study
      with the active study supplement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Standard Deviation Score (SDS)</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Height-SDS</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight SDS</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI SDS</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>IGHD - Isolated Growth Hormone Deficiency</condition>
  <condition>Growth Retardation</condition>
  <arm_group>
    <arm_group_label>Nutritional Standardized Supplementation Formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low caloric formula (Powder added to water) without added vitamins and mineral</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutritional supplementation standardized formula</intervention_name>
    <description>Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake</description>
    <arm_group_label>Nutritional Standardized Supplementation Formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Low caloric formula (Powder added to water) without added vitamins and mineral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GH treatment for at least 24 months due to IGHD. Confirmed diagnosis of GHD as
             determined by at least one GH stimulation test, defined as a peak GH level of ≤ 10
             ng/ml

          -  Boys: testicular volume &lt; 8ml; Girls: breast ≤ Tanner 3

          -  weight SDS &lt; 0

          -  BMI SDS &lt; 50 precentile for age and gender

          -  Signing inform consent forms

        Exclusion Criteria:

          -  Other indication for GH treatment.

          -  Bone age: boys&gt;13.5, girls&gt;11.5.

          -  Any known morbidity: chronic disease dysmorphic syndromes, bone diseases, organic
             brain diseases, neurological disease, past or current malignancy, chronic cardiac,
             renal or pulmonary problems, metabolic disorders.

          -  Any known gastrointestinal problem including absorption problems.

          -  Any chronic treatment with medication that might affect appetite, weight or growth
             (for example steroids) except from Ritalin use

          -  Any eating disorders and/or psychiatric disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Phillip, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schneider Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe Phillip, Prof, MD</last_name>
    <phone>972-3-9253282</phone>
    <email>mosheph@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alona Hamou, Msc</last_name>
    <phone>972-3-9253747</phone>
    <email>alonah@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Schnider children's medical center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Phillip, Professor</last_name>
      <phone>972-3-9253778</phone>
      <email>mosheph@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Moshe Phillip, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Revital Nimri, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liat De Vries, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liora Lazar, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tal Oron, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariel Tenennbaum, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shlomit Shalitin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judit Nir, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naama Fish, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sari Karpel, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon Demol, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Muller, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

